Bio-Rad Laboratories, Inc. BIO.B Clinical Diagnostics — Depreciation, Depletion and Amortization
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories, Inc.'s clinical diagnostics — depreciation, depletion and amortization.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories, Inc.'s clinical diagnostics — depreciation, depletion and amortization?
- Bio-Rad Laboratories, Inc. (BIO.B) reported clinical diagnostics — depreciation, depletion and amortization of $22.6M in Q1 2026.
- How has Bio-Rad Laboratories, Inc.'s clinical diagnostics — depreciation, depletion and amortization changed year-over-year?
- Bio-Rad Laboratories, Inc.'s clinical diagnostics — depreciation, depletion and amortization increased by 7.1% year-over-year, from $21.1M to $22.6M.
- What is the long-term trend for Bio-Rad Laboratories, Inc.'s clinical diagnostics — depreciation, depletion and amortization?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories, Inc.'s clinical diagnostics — depreciation, depletion and amortization has grown at a 2.2% compound annual growth rate (CAGR), from $82.8M to $90.4M.
- What does clinical diagnostics — depreciation, depletion and amortization mean?
- The non-cash cost of using up equipment and intangible assets in the diagnostics segment.
- How do you interpret clinical diagnostics — depreciation, depletion and amortization?
- High levels relative to revenue may indicate a capital-intensive business model or recent heavy investment in infrastructure.
- How does clinical diagnostics — depreciation, depletion and amortization compare across companies?
- Standard expense item; used to calculate EBITDA and assess capital intensity.